New Edition of NABCO Breast Cancer Resource List Is Now Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

NEW YORK--The National Alliance of Breast Cancer Organizations (NABCO) has just published the 1996-1997 edition of the NABCO Breast Cancer Resource List, made possible through an educational grant from Glaxo Wellcome Inc

NEW YORK--The National Alliance of Breast Cancer Organizations(NABCO) has just published the 1996-1997 edition of the NABCOBreast Cancer Resource List, made possible through an educationalgrant from Glaxo Wellcome Inc.

At more than 75 pages, it is NABCO's most comprehensive breastcancer resource guide to date. The booklet includes educationaland resource information for both the lay public and health careprofessionals, as well as a list of 350 breast cancer supportgroups nationwide. Many of the more than 2,000 listed publications(books, brochures, and videos) are available free or at low cost.

To obtain a copy, please send a self-addressed mailing label anda $3.00 check to NABCO, 9 East 37th Street, New York, NY 10016.Please indicate if you prefer the waiting room version markedwith the legend "Display Copy."

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content